A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability and efficacy of
combretastatin A4 phosphate (CA4P), also known as fosbretabulin, in combination with
bevacizumab (Avastin), carboplatin and paclitaxel in patients with chemotherapy naïve
non-small cell lung cancer (NSCLC). This is a randomized parallel arm study. All participants
will receive carboplatin, paclitaxel and bevacizumab, and half will additionally receive
CA4P. Patients who complete the first 6 cycles of therapy and have not experienced disease
progression will receive maintenance therapy with bevacizumab alone or with bevacizumab plus
CA4P.
The rationale for this study is the potential additive or synergistic actions of vascular
disrupting agents like CA4P with anti-angiogenic agents like bevacizumab.